Every 10-Q that Delcath Sys (DCTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DCTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DCTH filings page.
Delcath Systems, Inc. reported continued profitability for the quarter ended June 30, 2026, driven by growing adoption of its liver cancer therapies. Quarterly revenue was $29,133 (in thousands), up from $24,156 (in thousands) a year earlier, with HEPZATO KIT contributing $27,161 (in thousands) and CHEMOSAT $1,972 (in thousands). Gross profit reached $26,148 (in thousands), and net income was $2,668 (in thousands), or $0.07 per diluted share.
Research and development expenses rose to $10,380 (in thousands) in the quarter and $20,204 (in thousands) year-to-date as the company advances Phase 2 trials in liver‑dominant metastatic colorectal and breast cancer. Selling, general and administrative expenses also increased with U.S. commercial expansion. Delcath ended June 30, 2026 with $47,521 (in thousands) in cash and cash equivalents and $48,381 (in thousands) in short‑term investments and states that these resources, plus operating cash flows, are expected to fund operations for at least 12 months. The company has repurchased 945,665 shares for about $9.0 million under a $25.0 million authorization, leaving roughly $16.0 million available.
Delcath Systems, Inc. reported first-quarter 2026 revenue of $24.99 million, up from $19.78 million a year earlier, driven by continued uptake of the HEPZATO KIT in the United States. CHEMOSAT contributed $1.75 million, roughly flat year over year.
Gross profit rose to $21.26 million, but higher research and development spending of $9.82 million and selling, general and administrative expenses of $13.07 million led to a net loss of $1.07 million, compared with net income of $1.07 million in the prior-year quarter.
The company ended March 31, 2026 with $41.3 million in cash and cash equivalents and $48.0 million in short-term investments, and believes this liquidity will fund operations for at least 12 months. Delcath is advancing Phase 2 trials of HEPZATO in liver-dominant metastatic colorectal and breast cancer and continues a share repurchase program, having bought back approximately $9.0 million of stock under a $25.0 million authorization.
Delcath Systems (DCTH) reported strong Q3 2025 growth as product revenue reached $20.6 million, up from $11.2 million a year ago. HEPZATO KIT drove results with $19.3 million, while CHEMOSAT contributed $1.3 million. Gross profit was $17.9 million.
The quarter showed a small operating loss of $0.4 million but net income of $0.8 million, aided by $0.8 million of net interest income. For the first nine months, revenue rose to $64.5 million (from $22.1 million), with operating income of $2.8 million and net income of $4.6 million, marking a turnaround from last year’s loss.
Cash and cash equivalents were $41.8 million and short‑term investments were $47.1 million at September 30, 2025. Operating cash flow was $14.3 million year‑to‑date, supported by warrant and option exercises in financing activities. The company reiterated it believes existing cash, investments, and operating cash flow are sufficient for at least 12 months. As of October 27, 2025, 35,313,718 common shares were outstanding.
Clinical updates included positive Phase 2 CHOPIN data combining CHEMOSAT with checkpoint inhibitors, and ongoing Phase 2 programs in liver‑dominant colorectal and breast cancers.
Delcath Systems, Inc. (DCTH) — Quarterly highlights (six months ended June 30, 2025)
Product revenue grew to $43.94 million for the six months (2024: $10.91 million) driven by HEPZATO KIT and CHEMOSAT; Q2 product revenue was $24.156 million (Q2 2024: $7.766 million). Gross profit was $37.78 million for six months and operating income was $3.232 million. Net income was $3.766 million for six months (Q2 net income $2.697 million). Cash and cash equivalents totaled $34.421 million and short-term investments $46.584 million (combined $81.005 million) at June 30, 2025.
Operations and development: FDA-approved HEPZATO (Aug 14, 2023); first commercial use Jan 2024. IND for Phase 2 mCRC cleared Dec 2024 (approx. 90 patients; enrollment H2 2025; hPFS readout end 2027). IND for Phase 2 mBC cleared Apr 28, 2025 (approx. 90 patients; enrollment Q4 2025; hPFS readout end 2028). CHEMOSAT received two-year reimbursement in Vastra Gotaland, Sweden (June 2025). On May 22, 2025 Delcath entered NDRA/PPA obligations including 340B pricing and Medicaid rebates effective July 1, 2025.